Latest news with #BioNeMo
Forbes
2 days ago
- Business
- Forbes
Nvidia Announces Massive New Initiatives in Pharma And Clinical Research
Nvidia has quickly become a leader in the AI ecosystem. Founder and CEO of Nvidia, Jensen Huang, announced today in his GTC Paris keynote that the company has inked two new large partnerships to advance the company's work in healthcare and life-sciences. The first is with European based global pharmaceutical giant, Novo Nordisk, to advance drug discovery and development efforts by leveraging an existing partnership with the Danish Centre for AI Innovation's (DCAI) Gefion AI supercomputer. Novo Nordisk will utilize Gefion and a variety of Nvidia platforms such as BioNeMo, Nim, and Omniverse to build and develop customized AI models, foster agentic AI workflows and even create simulation and digital twin environments to advance physical AI applications. The primary goal will be to use these tools to better understand potential drug candidates and structures in order to build molecular models that can further the drug discovery and development pipeline. Rory Kelleher, senior director of business development for life sciences at Nvidia, explains that drug discovery can claim massive benefits from generative AI, especially in the R&D space. Mishal Patel, senior vice president of AI and digital innovation at Novo Nordisk, comments that the combination of Gefion and Nvidia's computing platforms is an unprecedented approach and will enable the building of custom models that can truly empower better efficiency and efficacy. More generally, Gefion is a computational behemoth and has been used by numerous enterprises to advance their computing capabilities; for example, Danish startup Teton has been working with Nvidia and Gefion to build out an AI care companion for clinical settings. The second partnership that Nvidia announced today is with IQVIA to advance the use of AI agents in the clinical research and commercialization spaces. The companies will collaborate to launch multiple AI powered agents to accelerate pharmaceutical development workflows for biotech and medical device customers globally. Importantly, the new agents will be 'orchestrator agents,' meaning that they will act as supervisors for groups of 'sub-agents' that each have their own specialties; the supervising agent will route a received task to the appropriate sub-agent, enabling an efficient and automated workflow. Using this technology, IQVIA is hoping to tackle some of the hardest problems in the drug development and pharmaceutical workflows. For example, clinical trials often require a significant amount of work to launch and execute. Agents can help identify targets, develop a knowledge base using existing research databases and even review clinical data to better understand insights and automate the review process. Avinob Roy, vice president and general manager at IQVIA, explains that AI agents will transform the entire 'molecule to market' lifecycle. Overall, the news comes at a time when Nvidia's reach into the AI ecosystem has been incredibly impactful. The company indicated in its latest quarterly report a continuing surge in demand for its GPUs and hardware ecosystem. Though most traditionally a hardware giant, it has also increasingly diversified its work into the cloud and software ecosystems, furthering its moat in the AI space. Undoubtedly, there is stiff competition in the AI race. With regard to hardware alone, technology giants such as Google and Amazon depend heavily on Nvidia for its GPUs; however, the companies are also rapidly developing their own silicon products, such as Google's work with tensor processing units (TPUs) and Amazon's customized silicon products (i.e., Trainium, Graviton and Inferentia). With regard to healthcare and life-sciences more broadly, all of the large technology hyperscalers are investing billions of dollars in these fields. For example, one of the most prominent success stories is Alphabet's Isomorphic Labs and its work with drug development models. Companies like Microsoft are also rolling out new enterprise grade tools and infrastructure capabilities to empower traditional life-science companies. Indeed, the innovation is rapid and unprecedented. Despite the perception of a 'competition' however, there is no need for a clear cut winner. The reality of this progress across the entire spectrum of technology companies is that ultimately, both the healthcare and life-sciences industries stand to gain immense benefits.
Yahoo
19-03-2025
- Science
- Yahoo
Sapio Sciences Makes AI-Native Drug Discovery Seamless with NVIDIA BioNeMo
Integration of the NVIDIA BioNeMo platform enhances AI capabilities across the drug discovery lifecycle BALTIMORE, March 19, 2025--(BUSINESS WIRE)--Sapio Sciences, the science-aware™ lab informatics platform, today announced the integration of the NVIDIA BioNeMo platform into the Sapio Lab Informatics Platform. This integration brings AI-driven computational drug discovery directly into Sapio ELN (Electronic Lab Notebook), helping to streamline workflows and improve decision-making in drug discovery. With the BioNeMo platform, researchers can accelerate drug discovery by leveraging science-specific AI frameworks, pre-trained models, and generative AI tools to streamline the identification of potential drug candidates and improve target selection accuracy. NVIDIA BioNeMo provides scientists with a framework for training and deploying large biomolecular language models at supercomputing scale. The integration of BioNeMo into the Sapio Platform provides scientists with embedded in silico tools, enabling them to, for example, generate novel candidate molecules early in the research process and test their docking with a target protein. With AI-driven molecular simulations available within a single, unified workflow, researchers can streamline their processes, enhance innovation, and accelerate the transition from discovery to development. Within Sapio ELN, researchers can access BioNeMo NIM microservices to rapidly identify and optimize drug candidates using AI-driven molecular modeling, including AlphaFold2 NIM for predicting accurate 3D protein structures; MoIMIM NIM to enable the design and optimization of small molecules; and DiffDock NIM, an AI-powered docking model developed by MIT. These models provide scientists with easy access to AI-driven tools without extensive setup, ensuring faster, more efficient research workflows. Kevin Cramer, Founder, CEO & CTO at Sapio Sciences, commented: "AI innovation is advancing rapidly, but scientists are often forced to navigate fragmented tools with complex interfaces, slowing down research. Our integration of NVIDIA's powerful AI-driven tools directly into the Sapio Platform enables researchers to apply AI seamlessly into their experiments. Through this work, we are removing inefficiencies and equipping scientists with the tools to rapidly generate, analyze, and visualize both chemical and biological results." Kevin continued: "We are working with NVIDIA to equip scientists and researchers with the most advanced AI tools to drive innovation in life sciences. This collaboration is a major step toward making AI an integral part of the drug discovery process, helping researchers make faster, data-driven decisions and improve research outcomes." Anthony Costa, Director, Digital Biology at NVIDIA, commented: "Integrating BioNeMo into Sapio's AI-driven research platform gives scientists access to advanced generative AI models for drug discovery. With AlphaFold2, MoIMIM, and DiffDock NIMs, researchers can predict, optimize, and validate drug candidates with greater speed and accuracy. This work underscores AI's growing role in transforming pharmaceutical research and accelerating the path to breakthrough treatments." Integrating NVIDIA technologies into the Sapio Platform is one of the many ways Sapio Sciences is helping to improve and accelerate biopharma discovery, clinical diagnostics, and drug manufacturing. Find out more about the Sapio/NVIDIA integration here. About Sapio Sciences At Sapio Sciences, our mission is to improve lives by accelerating the entire drug lifecycle. Our cloud-based solutions—LIMS, ELN, and Scientific Data Management—are unified on a flexible, configurable, and AI-powered informatics platform, streamlining complex workflows, unifying scientific data, and enabling faster, smarter decisions across biopharma research and development, clinical diagnostics, and manufacturing. Trusted by global leaders and innovators worldwide, we support a wide range of best-in-class applications, from NGS and bioanalysis to bioprocessing, stability studies, histopathology, antibody discovery, and in vivo studies. Discover how Sapio Sciences can revolutionize your lab operations at and follow us on LinkedIn. View source version on Contacts Media contacts: Zyme Communications Anna BakewellTel: +44 (0)7801 098 242Email: Tim BrookHead of PR, Sapio SciencesTel: +44 (0)7760 766 213Email: press@
Yahoo
18-03-2025
- Business
- Yahoo
NVIDIA's AI Speeds Up MedTech's Digital Boom: 3 Stocks in Focus
The medical device industry is undergoing a profound change in 2025, driven by advancements in generative AI and agentic AI. At the forefront of this revolution are players like NVIDIA NVDA, whose AI computing platforms are accelerating AI-powered medical applications and capturing investors' attention. NVIDIA's Clara platform, powered by generative AI, is enabling real-time medical imaging enhancements and predictive diagnostics. Additionally, NVIDIA's BioNeMo, a generative AI model tailored for life sciences, is advancing drug discovery and biomarker identification, directly impacting the development of AI-integrated medical devices. In January, NVIDIA joined industry leaders across genomic research, drug discovery, clinical trials and patient care to discuss how predictive, generative and agentic AI are driving advancements in healthcare. Here we discuss three MedTech leaders, Resmed RMD, GE HealthCare GEHC and Medtronic MDT, which are embedding different forms of AI into their devices, allowing systems to autonomously analyze patient data, adjust treatment protocols and improve decision-making without constant human intervention. For instance, AI-driven insulin pumps and robotic surgical systems are becoming more adaptive, offering unprecedented precision in treatment. WHO currently estimates a projected shortfall of 11 million health workers by 2030. With the healthcare sector facing one of the most severe labor shortages, AI's role in optimizing workflows and improving patient care has become increasingly crucial. Regulatory bodies are fast evolving to accommodate AI-enabled devices, and the FDA and European MDR are working on new frameworks for approving autonomous systems in healthcare. The introduction of predetermined change control plans (PCCP) and other frameworks allows AI models to evolve post-market while maintaining compliance, thus accelerating industry-wide adoption. As a result, AI-powered medical devices are reaching the market faster while maintaining stringent safety standards. Apart from deals with NVDA, MedTech giants are also seen collaborating with AI leaders like Google Health and Microsoft to co-develop cutting-edge solutions. These alliances fast-track AI integration across imaging, diagnostics and device automation. Resmed: It is actively progressing in the field of utilizing digital health technology to convert big data into valuable information. The company has captured a significant foothold in the digital health market with approximately 21 billion nights of medical data in the cloud and 27 million 100% cloud-connectable medical devices sold in more than 140 countries worldwide. ResMed aims to improve 500 million lives through better residential healthcare by 2030. The company has been expanding AI products in AirView. It continues to expand its portfolio of AI-driven capabilities, as well as customer-facing AI products that will be launched into the market from its ecosystem. This $34.8 billion market cap stock has a Zacks Rank #2 (Buy) and a long-term expected earnings growth rate of 16%. In 2025, Resmed is expected to record an earnings growth rate of 22.7%. Over the past 60 days, the Zacks Consensus Estimate for RMD's 2025 earnings has moved up by 13 cents. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. ResMed Inc. price | ResMed Inc. Quote GE HealthCare: The company is actively using artificial intelligence and machine learning to provide clinical decision support and highly personalized therapies enabled by more precise diagnostics and remote patient monitoring. In the United States, hospitals and outpatient centers are accelerating purchases of advanced imaging systems, ultrasound devices and interventional solutions, supported by a need to upgrade aging infrastructure and enhance operational efficiency. The shift toward outpatient procedures, particularly in orthopedics, cardiology and surgical imaging, is fueling demand for C-arms, ultrasound and PET scanners. This $39.03 billion market cap stock has a Zacks Rank #3 (Hold) and a long-term expected earnings growth rate of 6.2%. In 2025, GE Healthcare is expected to record earnings growth of 4.7%. Over the past 30 days, the Zacks Consensus Estimate for GAHC's 2025 earnings has moved up by 4 cents. GE HealthCare Technologies Inc. price | GE HealthCare Technologies Inc. Quote Medtronic: It is also actively integrating AI across its portfolio to enhance clinical outcomes. The company's GI Genius system utilizes AI to assist physicians in detecting colorectal polyps during colonoscopies. Further, the Touch Surgery Enterprise platform is an AI-powered surgical video management and analytics system. This apart, Medtronic has developed adaptive deep brain stimulation systems that use AI to tailor electrical stimulation based on real-time neural activity. MDT, with a market capitalization of $119.6 billion, currently carries a Zacks Rank #3. It has a long-term expected earnings growth rate of 7.3%. In fiscal 2025, MDT is expected to record earnings growth of 5%. Over the past 30 days, the Zacks Consensus Estimate for Medtronic's fiscal 2025 earnings has moved up by a penny. Medtronic PLC price | Medtronic PLC Quote Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Medtronic PLC (MDT) : Free Stock Analysis Report NVIDIA Corporation (NVDA) : Free Stock Analysis Report ResMed Inc. (RMD) : Free Stock Analysis Report GE HealthCare Technologies Inc. (GEHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
1724913086-0%2FBeFunky-collage%5D_______-(15)1724913086-0.jpg&w=3840&q=100)
Express Tribune
20-02-2025
- Science
- Express Tribune
Nvidia unveils powerful AI system for genetic research
A smartphone with a displayed NVIDIA logo is placed on a computer motherboard in this illustration taken March 6, 2023. PHOTO:REUTERS AI chipmaker Nvidia and research partners have created what they call the largest artificial intelligence system yet for biological research, the company said on Wednesday, aiming to speed up breakthroughs in medicine and genetics. The new AI system, called Evo 2, can read and design genetic code across all forms of life. Scientists have high hopes that such AI technology will dramatically accelerate research by spotting patterns in vast amounts of data that would normally take years to analyze by hand. The system learned from nearly 9 trillion pieces of genetic information taken from over 128,000 different organisms, including bacteria, plants, and humans. In early tests, it accurately identified 90 percent of potentially harmful mutations in BRCA1, a gene linked to breast cancer. Scientists say this could help develop more precise treatments, including gene therapies that only target specific cells. The model was built using 2,000 Nvidia H100 processors on Amazon's cloud infrastructure. Developed with the Arc Instiftute and Stanford University, Evo 2 is now freely available to scientists worldwide through Nvidia's BioNeMo research platform. "Designing new biology has traditionally been a laborious, unpredictable and artisanal process," said Brian Hie, assistant professor at Stanford University. AFP
Associated Press
12-02-2025
- Business
- Associated Press
Positive Market Response in Asia Fuels Potential Revenue Growth for ABVC and BioKey, Marching Into Global Dietary Supplements Market of USD 75.35 Billion
NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focusing on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, today announced its participation in BioLive's (formerly known as TT Life) Health Talk Event, marking a significant milestone in the company's growth and its role in advancing innovative healthcare solutions by penetrating a new market in Asia. The event showcased BioKey's Maitake BLEX 404 Dietary Supplement, a groundbreaking therapy created for cancer combination treatment and to enhance immunity, in an effort to help improve the quality of life for cancer patients. BioKey, a wholly owned subsidiary of ABVC, has built considerable confidence in its product and gained traction in the Asian market. We believe the surge in orders for Maitake BLEX 404 from Asia is due to an increase in healthcare professionals' and patients' recognition of the product's potential to enhance cancer treatment effectiveness while boosting the immune system. The rising demand for this product presents a promising opportunity for revenue generation. Uttam Patil, Ph.D., the Chief Executive Officer of ABVC, expressed his excitement about the positive response, stating, 'We are thrilled by the strong demand for BioKey's products in Asia. The growing interest in our innovative cancer combination therapy and immunity-boosting solutions highlights the effectiveness and potential of our treatments. We believe this achievement opens new market opportunities and will contribute to ABVC's overall revenue, reinforcing our long-term growth strategy. The success of BioKey's products in Asia aligns with ABVC's vision of providing advanced healthcare solutions that enhance patients' quality of life worldwide. As BioKey continues to expand its presence in the region, we anticipate that increased orders will drive revenue growth, benefiting ABVC and positioning the company for continued success in the global biotech market.' BioLive's event highlighted ABVC and BioKey's commitment to providing innovative and effective therapies. It also stressed the significance of integrating cancer treatment with immunity-boosting methods. ABVC continues to focus on expanding its product portfolio and entering new markets to address the growing demand for novel healthcare solutions. BioKey, situated in the heart of Silicon Valley, is strategically positioned to leverage cutting-edge AI advancements in biotechnology. Drawing inspiration from NVIDIA Corporation's innovative projects, BioKey is exploring several AI-driven initiatives to enhance its research and development capabilities: Generative AI for Drug Discovery: By adopting generative AI models similar to NVIDIA's BioNeMo framework, BioKey aims to accelerate the design and optimization of novel drug candidates. We believe this approach will facilitate rapid generation of potential therapeutic compounds, streamlining the early stages of drug discovery. AI-Accelerated Genomic Analysis: BioKey plans to implement GPU-accelerated genomic workflows, utilizing platforms like NVIDIA Clara Parabricks. This integration is expected to significantly reduce the time required for genomic data analysis, which can expedite the identification of genetic targets for new therapies. Advanced Protein Structure Prediction: Inspired by tools like ESMFold, BioKey is investing in AI models that predict the three-dimensional structures of proteins from their amino acid sequences. Accurate protein modeling is crucial for understanding disease mechanisms and developing targeted treatments. Integration of AI in Laboratory Automation: Following the example of a rtificial intelligence integration with NVIDIA BioNeMo, BioKey is exploring the automation of molecular screening processes. This strategy aims to enhance the efficiency and accuracy of laboratory workflows, leading to faster validation of drug candidates. By aligning with these AI-driven strategies, BioKey is poised to advance its mission of delivering innovative biopharmaceutical solutions. Capitalizing on its advantageous location in Fremont, California, BioKey will collaborate with leading technology and biotech entities. [2] [3] Driving Growth in Expanding Markets ABVC BioPharma is strategically positioned in growing markets. According to a report by Vantage Market Research, the global dietary supplements market was valued at USD 152.3 billion in 2022 and is projected to reach USD 269.5 billion by 2030, fueled by expanding markets and a compound annual growth rate (CAGR) of 8.5% over the forecast period. [4] The global immunity booster supplement market was valued at approximately USD 27.19 billion in 2023 and is projected to grow to around USD 75.35 billion by 2033, with a notable compound annual growth rate (CAGR) over the next decade. [5] About ABVC BioPharma & Its Industry ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus(R)) under development. For its drug products, the Company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept trials through Phase II of clinical development. The Company's network of research institutions includes Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus(R), the Company intends to conduct global clinical trials through Phase III. Forward-Looking Statements This press release contains 'forward-looking statements.' Such statements may be preceded by the words 'intends,' 'may,' 'will,' 'plans,' 'expects,' 'anticipates,' 'projects,' 'predicts,' 'estimates,' 'aims,' 'believes,' 'hopes,' 'potential,' or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. None of the outcomes expressed herein are guaranteed. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to proceed to the next level of the clinical trials or to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors are urged to read these documents free of charge on the SEC's website at The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise. This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company's securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
